Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Preclinical data on bexicaserin show a dual mechanism—enhancing inhibitory while reducing excitatory neuronal activity—supporting broader antiseizure potential. Results are reported across preclinical models of focal, generalized motor, and absence seizures. Overall, the news is directionally positive but remains early-stage (preclinical), so near-term pricing impact is likely limited.